Connect with us

Indica, Sativa, Hybrid & More

Published

on


CBD Seeds

CBD marijuana seeds share characteristics with feminized, regular, or autoflowering varieties, but are distinguished by their higher CBD content compared to conventional varieties. Additionally, in many cases, the aim is to minimize the THC level so that they can be used for medicinal purposes.

However, these seeds never contain the adequate concentration of THC for use in legal CBD product production, which currently must be below 0.2%. For this purpose, hemp seeds are used. Despite this, CBD marijuana seed varieties still offer more relaxing and stress-relieving effects than other varieties.

Hemp Seeds

Unlike CBD seeds, hemp seeds always contain THC levels below 0.2%, ensuring a predominance of CBD. Also known as industrial hemp, this variety is used for CBD extraction and the production of therapeutic products. However, the CBD levels obtained from hemp never reach those achieved with CBD seeds.

Hemp seeds are not only used for obtaining cannabidiol but also for extracting strong fibers used in various industries, such as textile, paper, insulation, rope manufacturing, fuel, paints, cosmetics, among others. Additionally, hemp seeds are edible and can be consumed as oil, whole, raw, toasted, or ground into flour.

Fast Version Seeds

Like CBD marijuana seeds, Fast Version seeds have similar characteristics to regular or feminized varieties, but their life cycle is shorter than usual, allowing for harvesting before the first October frosts.

Indeed, many of these types of seeds can be combined. Sativa, indica, hybrid, or ruderalis varieties can be presented in feminized, regular, autoflowering, or Fast Version forms. Hemp seeds, on the other hand, belong to the sativa group.



Source link

Cannabis News

25 Billion Reasons (and Counting) on Why Big Pharma Hates Marijuana Legalization

Published

on

By


big pharma on cannabis legalization

Real Reason Pharma Hates Weed

Sometimes I forget that not everyone has the same relationship with cannabis as I do. After spending over two decades researching, writing about, and experiencing the medical benefits of this remarkable plant, it’s become as normal to me as taking a daily vitamin. Cannabis is simply part of my wellness toolkit – a natural remedy that promotes balance and healing in ways that continue to amaze me.

But then I catch myself. I remember that for most of the world, cannabis still lurks in the shadows of illegality. Despite the growing wave of legalization, countless people remain in the dark about its therapeutic potential, their understanding clouded by decades of propaganda and misinformation.

Much of this ignorance can be traced back to Big Pharma’s influence over mainstream media and medical research. Through carefully crafted narratives and cherry-picked studies, they’ve painted cannabis as nothing more than a dangerous drug of abuse – just some “hippie grass” with no real medical value. It’s a masterful stroke of corporate manipulation that has kept millions from exploring this ancient medicine.

However, the truth has a way of emerging, especially in our digital age. Recent studies are painting a very different picture of cannabis – one that has pharmaceutical executives breaking out in cold sweats. Not only is cannabis proving effective for a wide range of conditions, but it’s also leading patients to reduce or eliminate their dependence on prescription medications.

Today, we’re going to explore these groundbreaking findings and expose the real reason Big Pharma is terrified of cannabis legalization. When you see the data on how this simple plant is impacting their bottom line, you’ll understand why they’ve fought so hard to keep it illegal.

So grab your favorite strain (if you’re in a legal state, of course), and let’s dive into the fascinating world of medicinal cannabis. What you’re about to learn might just change how you think about this controversial plant – and the companies trying to keep it out of your hands.

A groundbreaking yearlong study just published in the Journal of Pain and Palliative Care Pharmacotherapy has caught my attention, and believe me, it should catch yours too. The research followed 96 patients over 12 months, tracking their experiences with prescribed medical cannabis for chronic pain and mental health conditions. What they found wasn’t just impressive – it was downright revolutionary.

Let’s dive into the numbers, shall we? Within the first six months, patients reported significant pain reduction and improved mental well-being that continued throughout the entire year. We’re not talking about minor improvements here – a whopping 91% of participants reported their pain was “at least a little better,” with 75% declaring it was either “much better” or “very much better.”

But here’s where things get interesting, especially if you’re a pharmaceutical executive. By the study’s end, 55% of participants had reduced their prescription pain medication use, and 45% had cut back on over-the-counter pain medicines. The side effects? Mostly just dry mouth and sleepiness. Compare that to the novel-length list of potential complications from typical prescription pain medications.

And this isn’t an isolated finding. A separate review published in Cureus found that cannabinoids provided significant relief from chronic pain (33% versus 15% with placebo) with “minimal to no side effects.” The researchers went so far as to call it a “life-changing alternative” to conventional pharmaceuticals.

Another recent study revealed that 57% of patients with chronic musculoskeletal pain found cannabis more effective than their other analgesic medications, with 40% reducing their use of traditional painkillers after starting cannabis. The American Medical Association’s own research showed “significant improvements” in quality of life for people with chronic conditions like pain and insomnia, with effects “largely sustained” over time.

See the pattern emerging? Across multiple studies, we’re consistently seeing two things: cannabis works, and when it works, people need fewer pharmaceutical drugs. This isn’t just about pain medication either – patients reported decreasing their use of medications for depression, anxiety, and sleep problems too.

For those of us who understand cannabis, these findings aren’t surprising. But for Big Pharma, they’re absolutely terrifying. When half your patient base starts reducing their medication use by 40-55%, that’s not just a dent in profits – it’s a crater.

But here’s the kicker: the numbers I’ve just shared with you are just the tip of the iceberg. In our next segment, we’re going to translate these percentage drops in medication use into cold, hard cash. We’ll see exactly why pharmaceutical companies are spending millions lobbying against cannabis legalization, and trust me, when you see the figures, you’ll understand why they’re sweating.

Because let’s be honest – this isn’t about patient welfare anymore. It’s about protecting profit margins. And nothing threatens those margins quite like a plant people can grow in their backyard.

 

Let’s put these numbers into perspective, shall we? When we look at just one category of pharmaceutical drugs – say, prescription pain medications – we’re talking about a market worth over $25 billion annually. Now, imagine watching 40-55% of your customers walking away, choosing instead to use a plant they might be growing next to their tomatoes. That’s the nightmare Big Pharma is facing.

Research indicates that pharmaceutical companies lose approximately $10 billion annually in states with medical marijuana programs. And that’s just the tip of the proverbial iceberg. As more states legalize and more people discover cannabis’s therapeutic potential, these losses are projected to grow exponentially.

But here’s what really keeps pharmaceutical executives up at night: they can’t monopolize cannabis like they do with their synthetic drugs. Sure, they can create cannabis-based medications (and they are), but they can’t patent the plant itself. Mother Nature, in her infinite wisdom, made cannabis remarkably easy to grow and process.

Think about it – any moderately skilled home grower can produce a variety of cannabis medicines right in their backyard. Want to make a topical salve for arthritis? Just infuse some cannabis in coconut oil. Need something for sleep? You can make your own tincture. Looking for anti-inflammatory benefits without the high? Raw cannabis juice or leaves will do the trick. No pharmaceutical company required.

This accessibility terrifies Big Pharma because it completely circumvents their carefully controlled production and distribution systems. You don’t need a sophisticated laboratory or millions in equipment to create effective cannabis medicine. You need soil, water, sunlight, and a little knowledge passed down through generations of growers.

Even more threatening is cannabis’s versatility. One plant can potentially replace multiple medications. A patient might use cannabis to manage their chronic pain (goodbye opioids), help them sleep (see ya, Ambien), and ease their anxiety (farewell, Xanax). That’s three revenue streams dried up from a single plant growing in someone’s garden.

And let’s not forget about raw cannabis consumption – a method that completely bypasses the need for processing altogether. Raw cannabis contains THCA and CBDA (the acidic precursors to THC and CBD), along with hundreds of other beneficial compounds including terpenes and flavonoids. These compounds offer significant therapeutic benefits without any psychoactive effects, essentially giving patients a nutrient-dense superfood that doubles as medicine.

This is the real reason behind Big Pharma’s anti-cannabis stance. It’s not about safety concerns or public health – it’s about protecting their bottom line from a plant that threatens their entire business model. Cannabis represents everything they fear: a natural, effective medicine that people can grow themselves, process in their kitchens, and use to treat multiple conditions without ever stepping foot in a pharmacy.

No wonder they’re spending millions on lobbying against legalization. When your profit margin is threatened by a plant that literally grows like a weed, you’ve got a serious problem on your hands.

JG

Now let’s write a 350-word conclusion entitled, “The Sticky Bottom Line”

 

In this segment focus on:

* I believe that everyone should have access to medicine they can grow. I even favor people growing their own opium, coca plant, psychedelic mushrooms, etc. This all in the name of bodily autonomy.

* Getting people off pharmaceuticals and taking health into their own hands is one of the best things that could happen for humanity.

* The science backs cannabis as a medicine, and each day that we continue to stall on making it widely available to people in need, is another day we perpetuate suffering for no reason other than greed.

 

 

Here’s a 350-word “Sticky Bottom Line” conclusion:

 

Let me be perfectly clear about where I stand: I believe every human being should have the right to grow their own medicine. Whether it’s cannabis, poppies, coca plants, or mushrooms, bodily autonomy means having sovereignty over your own consciousness and the ability to manage your own health. The idea that we need corporate gatekeepers to mediate our relationship with plants that have been used medicinally for thousands of years is not just absurd – it’s morally reprehensible.

 

The evidence we’ve explored today paints a crystal clear picture: cannabis works. It helps people manage pain, reduces anxiety, improves sleep, and allows countless patients to reduce or eliminate their dependence on pharmaceutical drugs. This isn’t just anecdotal anymore – it’s backed by rigorous scientific research. Yet millions still suffer needlessly because an industry more concerned with profits than patients continues to obstruct access to this healing plant.

 

Every day we delay full cannabis legalization, we’re choosing to prioritize corporate profits over human welfare. We’re forcing people to remain dependent on expensive, often addictive medications when they could be growing a safer alternative in their backyard. We’re maintaining a system where healthcare is a privilege rather than a right, where healing is commodified and monetized rather than democratized and accessible.

 

The shift away from pharmaceutical dependence toward natural, self-grown medicine represents one of the most significant opportunities for improving human health and wellbeing in our lifetime. It’s not just about cannabis – it’s about reclaiming our right to heal ourselves, to make informed choices about our health, and to access the therapeutic tools nature has provided us.

 

The science is clear. The benefits are proven. The only thing standing between millions of people and potential relief is a profit-driven system that values patents over patients. It’s time to choose: will we continue to support a system that prioritizes profits over people, or will we finally embrace the healing power of plants that grow freely under the sun?

The choice, like the bottom line, is sticky indeed.

Inspiration: https://www.marijuanamoment.net/medical-marijuana-improves-chronic

-pain-and-mental-health-symptoms-while-reducing-prescription-drug-use-study-shows/

 

BIG PHARMA BLOCKING MARIJUANA LEGALIZATION, READ ON…

WHY BIG PHARMA HATES MARIJUANA

WHY BIG PHARMA HATES WHEN PEOPLE SWITCH TO WEED!



Source link

Continue Reading

breaking news

South Africa: Stop arresting cannabis users, Human Rights Commission urges police after complaints about arrests from Rastafarian community.

Published

on

By


The SA Human Rights Commission (SAHRC) has written to national police commissioner Gen Fannie Masemola to express concern over the ongoing arrests of cannabis users and Rastafarians despite a law permitting the private cultivation and use of cannabis by adults.

The private use, possession and cultivation of cannabis by adults was decriminalised in 2018, with President Cyril Ramaphosa signing the Cannabis for Private Purposes Act on May 28 this year.

However, the SAHRC has received complaints about arrests from cannabis users and the Rastafarian community.

“As the festive season approaches, the SAHRC reminds law enforcement, in particular the SA Police Service and the National Prosecuting Authority, that the arrest and/or prosecution of adults for the private use, possession or cultivation of cannabis, as well as making assumptions about dealing, is inconsistent with the law and national operational directives. Such arrests and/or prosecutions could lead to human rights violations being perpetrated by law enforcement,” the SAHRC said.

Since August last year, a directive issued by Masemola titled “Arrests by the SA Police Service for Cannabis — Related Matters” recognised legislation did not prescribe the quantity of the cannabis in possession of or cultivated by an adult to presume it was the unlawful dealing of cannabis.

“Therefore, as things stand, the directive directs that adults may not be arrested on the presumption of dealing in cannabis,” the SAHRC said.

The SAHRC urged the department of justice and constitutional development to consult with the Rastafari and other cannabis-using communities to draft regulations for the Cannabis for Private Purposes Act. This includes advice on a specific commencement date for the act, which has yet to come into effect.

https://www.timeslive.co.za/news/south-africa/2024-12-24-stop-arresting-cannabis-users-sa-human-rights-commission-urges-police/



Source link

Continue Reading

Consumption

Breaking the Grass Ceiling: Pot firms rethink strategy as young women lead cannabis use

Published

on

By


Young women are consuming more pot than men for the first time in a historic shift in the $30 billion U.S. cannabis industry, prompting companies to revamp products and step up investments. Top cannabis retailers told Reuters they’ve started refocusing shelf space toward products that have proved popular with women, including edibles, tinctures, topicals, and beverages, in the hopes that any resulting rise in costs will pay off in the longer term.



Source link

Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media